The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Cantourage introduces second Clever Leaves medical cannabis product to the German market
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Subscribe To Our Newsletter & Stay Updated
